Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4979675 | 0.91 | ALDH1A1 (0.48) | MAPTHSP90AB1KDM4ELMNATSHR | |
| SCHEMBL4977998 | 0.90 | HSP90AB1 (0.44) | MAPTHSP90AB1KDM4ETSHRKMT2A | |
| SCHEMBL4981991 | 0.88 | MAPT (0.49) | MAPTHSP90AB1KDM4ELMNAKMT2A | |
| SCHEMBL4979696 | 0.87 | KDM4E (0.52) | MAPTHSP90AB1KDM4EPOLBPDGFRB | |
| SCHEMBL4979742 | 0.86 | ALDH1A1 (0.48) | MAPTHSP90AB1KDM4ESMN1; SMN2LMNA | |
| SCHEMBL4977156 | 0.86 | HSP90AB1 (0.43) | MAPTHSP90AB1KDM4EPOLBLMNA | |
| SCHEMBL4980682 | 0.85 | ALDH1A1 (0.51) | MAPTHSP90AB1KDM4ELMNAPDGFRB | |
| SCHEMBL4976981 | 0.85 | MAPT (0.51) | MAPTHSP90AB1KDM4EPOLBLMNA | |
| SCHEMBL4980672 | 0.85 | ALDH1A1 (0.51) | MAPTHSP90AB1KDM4ELMNAPDGFRB | |
| SCHEMBL4976800 | 0.85 | MAPT (0.43) | MAPTHSP90AB1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | HRH3, HRH4, HRH2 | MAPT 2301/4885HSP90AB1 2652/4885KDM4E 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.